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Abstract
We validate the utility of ion mobility to measure protein conformational changes induced by the 
binding of glycosaminoglycan ligands, using the well characterized system of Antithrombin III 
(ATIII) and Arixtra, a pharmaceutical agent with heparin (Hp) activity. Heparin has been used as a 
therapeutic anticoagulant drug for several decades through its interaction with ATIII, a serine 
protease inhibitor that plays a central role in the blood coagulation cascade. This interaction 
induces conformational changes within ATIII that dramatically enhance the ATIII-mediated 
inhibition rate. Arixtra is the smallest synthetic Hp containing the specific pentasaccharide 
sequence required to bind with ATIII. Here we report the first travelling wave ion mobility mass 
spectrometry (TWIMS) investigation of the conformational changes in ATIII induced by its 
interaction with Arixtra. Native electrospray ionization mass spectrometry allowed the gentle 
transfer of the native topology of ATIII and ATIII–Arixtra complex. IM measurements of ATIII 
and ATIII–Arixtra complex showed a single structure, with well-defined collisional cross section 
(CCS) values. An average 3.6% increase in CCS of ATIII occurred as a result of its interaction 
with Arixtra, which agrees closely with the theoretical estimation of the change in CCS based on 
protein crystal structures. A comparison of the binding behavior of ATIII under both denaturing 
and non-denaturing conditions confirmed the significance of a folded tertiary structure of ATIII 
for its biological activity. A Hp oligosaccharide whose structure is similar to Arixtra but missing 
the 3-O sulfo group on the central glucosamine residue showed a dramatic decrease in binding 
affinity towards ATIII, but no change in the mobility behavior of the complex, consistent with 
prior studies that suggested that 3-O sulfation affects the equilibrium constant for binding to 
ATIII, but not the mode of interaction. In contrast, nonspecific binding by a Hp tetrasaccharide 
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showed more complex mobility behavior, suggesting more promiscuous interactions with ATIII. 
The effect of collisional activation of ATIII and ATIII–Arixtra complex were also assessed, 
revealing that the binding of Arixtra provided ATIII with additional stability against unfolding. 
Overall, our results validate the capability of TWIMS to retain the significant features of the 
solution structure of a protein–carbohydrate complex so that it can be used to study protein 
conformational changes induced by the binding of glycosaminoglycan ligands.
Introduction
Heparin (Hp) and heparan sulfate (HS) are highly sulfated, linear polysaccharides, 
consisting of disaccharide repeat units of 1–4 linked hexuronic acid and N-acetyl-
glucosamine, and are members of a class of carbohydrates known as glycosaminogly-cans 
(GAGs).1 The sequence of Hp and HS features three types of domains: highly sulfated (NS) 
domains, less or non-sulfated N-acetylated (NA) domains and partially sulfated domains 
(NA/NS). Some of these domains are selectively recognized by over hundreds of secreted 
and membrane associated human proteins.2–5 By regulating the location, stability and 
activity of these interacting proteins, Hp and HS play crucial role in many important 
physiological and pathological processes.6
The Hp/HS induced, allosteric activation of Antithrombin (ATIII) is the most studied and 
best understood example of a specific GAG–protein interaction. The anticoagulant property 
of Hp was discovered in 1916, and it has been used for prophylaxis and treatment of venous 
thrombosis, thrombophlebitis and embolism since 1940s.2 Antithrombin III (ATIII), a 58.2 
kDa N-glycosylated mono-chain protein in the serpin (serine protease inhibitor) family of 
proteins, serves as a principal regulator of blood coagulation serine and cysteine proteinases 
including factor IXa, factor Xa, and thrombin. The inhibitory activity of ATIII is repressed 
until it is activated by Hp/HS cofactor, either from therapeutic Hp or endothelial cells 
surface HS proteoglycans at the site of a vascular injury.7 The native tertiary structure of 
ATIII is centered at a five-stranded β-sheet A, in which the N-terminal hinge of a reactive 
center loop (RCL) is initially buried with an orientation unfavorable to react with target 
proteinases.8 Recent studies also found that the constraint of the RCL also intensifies the 
repulsive exosite interactions which counteracts the favorable interaction between 
proteinases and exosite determinants on strand 3 of sheet C surrounding the RCL.9
The activation of ATIII occurs via its interaction with Hp, and more specifically, with a 
unique pentasaccharide sequence with a rare 3-O sulfo group.2 Upon binding of Hp/HS, a 
local conformational change at the Hp-binding site (the N-terminal region, the N-terminal 
end of helix A and all of helix D) is triggered. This further induces conformational changes 
on the proteinase binding site on ATIII.10,11 As a result of the allosteric activating structure 
arrangement, the RCL is released and the equilibrium between favorable and repulsive 
exosite interactions shifts to the favorable side.12 Therefore, the formation and stabilization 
of ATIII–proteinase complex are promoted. The inhibitory rate of ATIII can be accelerated 
up to 150–500-fold by the binding of the specific Hp pentasaccharide domain against factors 
Xa, IXa and VIIa, and this rate can be accelerated up to 2000–200 000-fold by full-length 
Hp.13
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As shown in the case of the interaction between ATIII and Hp/HS, a protein–ligand or 
protein–protein interaction is often characterized by a three dimensional conformational 
change of the protein in response to a specific biological function. Conventional solid-phase 
method (X-ray crystallography) and solution-phase method (NMR spectroscopy) allow 
elucidation of structural details of protein and protein complex, and the structures of ATIII 
and ATIII–Arixtra complex have been characterized in this fashion. However, there are 
issues including difficult sample preparation, lengthy data analysis and low sample 
compatibility, which reduce the widespread applicability of these methods to a wide variety 
of protein–GAG complexes.14
Ion mobility mass spectrometry (IMMS) is a rapid, sensitive and high-throughput gas-phase 
technique combing the advantages of both ESI mass spectrometry and ion mobility 
separation, and has gained much attention and recognition in the field of structural and 
dynamical biology.15 IMMS separates gas-phase ions according to their mobility, an 
intrinsic property determined by size, shape and charge state of ions.16 Travelling wave ion 
mobility spectrometry (TWIMS) is a commonly-used approach for IMMS, and is a 
commercially available product. In TWIMS, ion mobility separation takes place in an ion 
guide filled with a neutral gas. A radially confining potential barrier stops ion diffusion 
away from the path of the ion beam, while a continuous series of low voltage pulses called 
travelling waves push ions through the device.17 Protein ions with larger collisional cross 
section (CCS) have lower mobility, undergo more frequent collisions and fall behind the 
traveling waves, with the result that they are transmitted more slowly than ions with higher 
mobility. The drift time of a protein ion can be related to its CCS and conformation though 
calibration with standards. The biological relevance of the measured CCS can be validated 
by comparison with theoretical CCSs generated from NMR or X-ray crystal structures.18
Due to the advantage of TWIMS to experimentally estimate the CCS of a gas phase ion in a 
rapid and sensitive manner, it has been applied by a number of researchers for studies of 
protein interactions: Leary and coworker have applied TWIMS to detect differences in the 
conformations of two classes of chemokines as well as the effect of degree of sulfation of 
Hp-like oligomers on Hp-chemokine interactions;19 Ruotolo and coworkers have applied 
TWIMS to study the gas-phase conformational stability of wild-type tetrameric transthyretin 
and its disease-associated variants with and without ligand binding;20 Robinson and 
coworkers have applied TWIMS to measure the quaternary structure of the trp RNA binding 
protein (TRAP) complex and how the addition of tryptophan or RNA enhances the stability 
of its ring topology;21 Heck and coworkers have applied TWIMS to measure the CCSs of 
oligomeric viral capsid assembly of Hepatitis B virus (HBV) and norovirus;22 Russell and 
coworkers have applied TWIMS to study how the binding of metal ions influences the 
conformation transition of human metallothionein-2A (MT) protein;23 Bowers and 
coworkers have used IMMS to investigate the quaternary structure and self-assembling 
pathways of amyloid-β protein assemblies.24 Though there are concerns regarding the extent 
to which the structure of a gas-phase ion matches the native structure of a protein in 
solution, numerous studies have established a good correspondence between the two, 
particularly for the short time periods of an IMMS measurement, and under carefully 
controlled experimental conditions.25
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The ATIII–Hp interaction featured by its well-studied conformational change and high 
binding specificity represents an excellent model to test the applicability of the TWIMS 
approach to examine conformational changes associated with GAG–protein interactions. In 
this study, we applied the method of TWIMS to investigate the nature and extent of 
conformational change within ATIII induced by the binding of Arixtra, a synthetic analogue 
of the Hp pentasaccharide sequence known to bind this protein with high specificity.26 
TWIMS experiments were performed in order to answer these questions: Can the solution 
structure of ATIII survive the gas-phase environment in TWIMS and still maintain its 
activity to bind with Hp? Is TWIMS capable of detecting the small difference in CCS for 
ATIII that is induced by the binding of Arixtra? Do gas-phase ATIII ions exhibit selective 
binding with Arixtra compared to other structurally-similar compounds? Do the complexes 
of ATIII and Hp oligosaccharides lacking some of the features of the specific binding motif 
show similar or different behaviors in their ion mobility? Collectively, the answers to the 
following questions provide insight into the utility of an IM approach, and more specifically, 




All chemicals and solvents (ammonium acetate, methanol, water and formic acid) were of 
HPLC grade and purchased from Sigma-Aldrich. AT III was purchased from Aniara/
Hyphen Biomed as lyophilized powder (West Chester, OH). Stock solution of ATIII was 
made by dissolving the lyophilized protein into HPLC-grade water and then stored at −80 
°C. Arixtra was purchased from the hospital formulary and desalted on a BioGel P2 column 
BioRad (Hercules, CA, USA) before use. Modified Arixtra was chemoenzymatically 
synthesized as previously described.27 The Hp tetrasaccharide was produced from naturally 
occurring source as previously described.28 Protein calibrants (myoglobin from equine heart, 
cytochrome c from equine heart, avidin from egg white, concanavalin A from Canavalia 
ensiformis and bovine serum albumin) were purchased from Sigma-Aldrich as lyophilized 
powder.
Sample preparation
For MS analyses under denaturing conditions, ATIII was diluted in a water/methanol/formic 
acid solution (49.5 : 49.5 : 1, v/v/v) to a final concentration of 3 μM. For MS analyses under 
non-denaturing conditions, ATIII was diluted in 20 mM ammonium acetate buffer, pH 6.8, 
to a final concentration of 10 μM. ATIII–Hp complex was obtained by incubating ATIII 
with Arixtra or other Hp oligosaccharides at a molar ratio of 1 : 1 at room temperature. 
Protein calibrants were diluted in either denaturing solution or non-denaturing solution to a 
final concentration of 10 μM.
IMMS measurement
NanoESI-IMMS experiments were performed using a quadrupole-TWIM-TOF hybrid mass 
spectrometer (Synapt G2 HDMS, Waters Corp., Manchester, UK) in positive ionization 
mode. Protein samples were injected into the nanoESI source through a fused-silica emitter 
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(PicoTip New Objective, Woburn, MA) with a flow rate varying from 0.2–0.5 μl min−1. 
Experimental parameters were carefully tuned to prevent the protein and protein complex 
from unfolding or losing integrity due to extensive activation while keeping substantial ion 
transmission. The applied experimental parameters were: capillary voltage, 1.5 kV; 
sampling cone voltage, 30 V; extraction cone voltage, 5 V; source temperature, 90 °C; flow 
rate of nitrogen in the IM ion guide, 50 ml min−1; flow rate of helium in the helium cell, 180 
mL min−1; Trap collision energy, 0 V; transfer collision energy, 0 V. Different sets of wave 
height and corresponding wave velocity were used to optimize the mobility separation. The 
drift times of the calibrants and ATIII samples were measured when identical experimental 
conditions were stringently applied. Data analysis was performed with Mass-Lynx 
4.1(Waters Corp., Manchester, UK).
CCS calibration
The biggest challenge of IMMS using TWIMS is proper calibration. Mobility is a unique 
property for a given ion, and depends only on the features of a protein ion and neutral gas 
(mass, charge, size and shape). The measured drift time of an ion is under the influence of 
many other factors, including experimental conditions (magnitude and velocity of travelling 
wave, pressure of neutral gas, temperature of the source and ion guide). Since the electric 
field in TWIMS is not uniform due to the existence of travelling wave voltages whose 
electric potential is changing over time and position within the IM ion guide, drift time 
acquired using TWIMS cannot be converted directly into a CCS. Instead, the CCS of an 
analyte needs to be determined based on an empirical relationship between the drift times of 
protein calibrants and their known CCSs obtained previously by conventional drift time 
IMS.29
Experimental CCSs were calibrated, as described in several published protocols.18,29 
Briefly, the CCSs of calibrants were corrected for their charge state and reduced mass with 
respect to the buffer gas. The drift times were corrected for mass-dependent flight time spent 
in the transfer ion guide and TOF mass analyzer and mass-independent flight time spent in 
the transfer ion guide. The natural logarithm of corrected CCSs were plotted against the 
natural logarithm of corrected drift times and a mathematical formula ( ) 
was derived. The calibration coefficient A was extracted to calculate the effective drift times 
.18 A calibration curve was generated by plotting the literature CCSs 
as a function of . As suggested by Ruotolo et al., the correlation coefficient R2 of the 
calibration curve should be higher than 0.98.18 The experimental CCS of the analyte ion was 
derived from this calibration curve based on the measured drift time.
Another intrinsic problem for this experiment is that the calibrant library uses CCSs which 
were measured in helium while the TWIMS measurement uses an IM ion guide filled with 
nitrogen. However, the absolute error of CCS calibration derived from measuring CCS in 
different gases can be minimized when appropriate separation parameters are applied and 
when protein calibrants used to construct calibration curves are carefully selected.30,31
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We have noted that CCS estimation was substantially improved by using native protein 
calibrants in the calibration, compared with using only denatured myoglobin (data not 
shown). Previous studies showed that CCS calibrated using only denatured calibrants were 
strongly influenced by separation conditions in TWIMS experiment. Therefore, including 
native calibrants of similar shape and nature as the analytes in the calibrant set greatly 
increased the accuracy of calibrated CCS of native ATIII and ATIII–Hp complex.32
A selected set of native and denatured protein calibrants, with a mass range from 12 kDa to 
102 kDa and a CCS range from 2303 Å2 to 5550 Å2 were employed. The charge states and 
literature CCSs of these protein calibrants used to construct the calibration curve are listed in 
Table 1, selected from the Collision Cross Section Database, Bush Lab.33 The mass range 
and CCS range chosen were broad enough to bracket the masses and drift times of ATIII 
and ATIII–Hp complex ions (Fig. 1), so no extrapolation of the calibration curve is 
necessary.
The separation parameters controlling the ion mobility separation were optimized, so that 
they fit both the analytes and calibrants. Multiple sets of separation parameters were applied 
to exclude the effect of electric field on the drift time measurement. The calibration curves 
constructed at wave height of 13, 15 and 17 V are shown in Fig. 1. R2 values of 0.9919, 
0.9944 and 0.9966 were observed for each trend line.
Theoretical calculation of CCSs
The missing residues in the PDB files for the ATIII–Arixtra complex (PDBid: 1E03) and 
ATIII (PDBid: 1E05)34 were added using MODELLER.35 In the complex, the protein was 
missing 5 residues from the N-terminus and 8 residues from a disordered portion of the N-
terminus. The free protein lacked 2 residues from the N terminus and 12 residues from the 
disordered region that was missing in the protein in complex with Arixtra. Both forms also 
lacked one residue at the C-terminus.
Topology and coordinate files for the ATIII–Arixtra complex and free ATIII were generated 
using the tLeap program, employing the Protein ff99SB36 and GLYCAM06 (version j)37 
parameters for the protein and GAGs, respectively. The net charge on each system was 
neutralized with the addition of appropriate number of Na+ ion. The systems were solvated 
with TIP3P water model38 in an octahedron box extending to at least 12 Å from any atom of 
the solute.
All MD simulations were performed with the GPU implementation of pmemd, 
pmemd.cuda_SPDP39 in Amber14.40 Energy minimization of the solvent was performed in 
an NVT ensemble (1000 steps of steepest descent, 24 000 steps of conjugate gradient), 
followed by a full system energy minimization (1000 steps of steepest descent, 24 000 steps 
of conjugate gradient). The systems were heated from 5 K to 300 K over 60 ps in an NVT 
ensemble, with a weak positional restraint (10 kcal mol−1 Å−2) on the atoms in the solute. A 
Berendsen-type thermostat41 with a time coupling constant of 1 ps, was utilized for 
temperature regulation. Equilibration and production was performed at constant pressure 
(NPT ensemble; 1 atm), with a pressure relaxation time of 1 ps. After the heating step the 
restraints were removed from the solute atoms, and the entire system was allowed to 
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equilibrate at 300 K for 1 ns. All covalent bonds involving hydrogen atoms were constrained 
using the SHAKE42 algorithm, allowing a simulation time step of 2 fs. Scaling factors for 1–
4 interactions were set to the recommended values of 1.0 and 1.2 for the GAG37 and 
protein,36 respectively, and a non-bonded interaction cutoff of 8.0 Å was employed. Long-
range electrostatics were computed with the particle mesh Ewald (PME) method. Data were 
collected for 20 ns for both the systems. Post processing of the MD simulations was 
performed using ptraj43 module of Amber and graphical representations of the results were 
generated with VMD.44
Theoretical CCSs of ATIII and ATIII–Arixtra complex were calculated on 30 frames from 
the last 5 ns of the simulation using MOBCAL.45 Both the projection approximation (PA),45 
and trajectory method (TM)46 were employed for the calculations. Additionally, for the 
simulation of ATIII in complex with Arixtra, the CCS was also calculated after removal of 
the ligand, in order to estimate the contribution of protein conformational change to the 
overall change in the CCS.
Results and discussion
Native mass spectrometry of unbound and Arixtra-bound ATIII
ATIII was first analyzed under non-denaturing condition without the addition of any Hp 
(Fig. 2a). The protein was represented by a single charge state envelope, indicating that only 
protein monomers existed under this experimental condition. Five charge states were 
observed from +17 to +13 over a range of m/z 3300–4700. Since the charge states detected 
by using native MS depend opon the three dimensional conformation of the protein ion, a 
narrow distribution of lower charge states indicates a folded and compact conformation with 
fewer basic sites exposed for protonation.47 The three charge states, +16 to +14, were 
selected for further investigation since they were the most dominant charge states with 
relatively higher S/N. An average molecular weight of 57 876 ± 6 Da was obtained, in 
agreement with the literature molecular weight of ATIII (57 875 Da).48
ATIII was next incubated with a small molar excess of Arixtra. Two incubating times were 
examined to monitor the progress of the binding reaction: 1 h (Fig. 2b) and 12 h (Fig. 2c). 
The binding of Arixtra by ATIII did not change the charge state distribution observed for the 
native protein. An additional peak was observed for each charge state, corresponding to the 
formation of Arixtra–ATIII complex. An average mass increase of 1512 Da was measured 
for the new peaks, in good correspondence to the molecular weight of a single Arixtra 
molecule (1505 Da). To confirm the binding stoichiometry, titration experiments with 
different molar ratios were examined, but increasing the amount of Arixtra did not result in 
the formation of any new peaks. After 12 h of incubation, only the peaks corresponding to 
Arixtra bound to ATIII in a 1 : 1 ratio were present (Fig. 2c). Since longer incubation time 
allowed the binding reaction to go to completion, this result indicates that the ATIII only 
presents one binding site for Arixtra, in accordance with the 1 : 1 binding stoichiometry 
between ATIII and Arixtra reported previously.49 All of these observations suggest that the 
solution structure of ATIII survives the ionization process and the environment of the 
TWIMS instrument.
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Interestingly, the intensity ratio between ATIII with and without Arixtra varied with charge 
state. The ratio for +17, +16, +15 and +14 were 0.69, 1.02, 3.07 and 5.75, respectively. It is 
evident that the intensity ratio increases with the decrease of charge state, suggesting 
weakening in the binding affinity with the increase of charge state. One possible explanation 
is that the lower charge states are more representative of the native structure of ATIII due to 
a lowering of charge–charge repulsion.
TWIMS of ATIII and its complex with Arixtra
To investigate whether the protein conformational change caused by the interaction between 
ATIII and Arixtra can be detected by TWIMS, ion mobility measurements were performed 
on the gas-phase ATIII and Arixtra-bound ATIII ions. The measured drift times of each 
charge state of ATIII and Arixtra-bound ATIII are shown in Fig. 3, at a wave height of 17 V. 
One narrow drift time distribution was observed for each charge state of ATIII, indicating 
the presence of a single compact and folded conformation for the ATIII ions. For Arixtra–
ATIII complex, a single narrow peak at higher drift time was observed for each charge state, 
implying that binding of Arixtra causes a change in the folded conformation of ATIII, 
leading to a specific structure with a larger CCS. These observations suggest that the tertiary 
structures of ATIII and the non-covalent Arixtra–ATIII complex are stable in the TWIMS 
experiment.
After calibration, the measured drift times for ATIII and its complex with Arixtra have been 
converted to CCSs, shown in Table 2. For each charge state, the reported CCS was an 
average from triplicate experiments, and was found to have a 0.6% relative standard 
deviation. The binding of Arixtra induces a 3.6% increase in CCS of ATIII, several times 
larger than the standard deviation in the measurements. The conformational change was 
highly reproducible, and was observed for each charge state, as well as for a variety of wave 
heights and wave velocities. The drift times and peak shape measured for residual bound 
ATIII, which is present at moderate abundance in the mass spectrum of the 1 hour mixture, 
Fig. 2b, were the same as the drift times measurements for the ATIII peaks in the mass 
spectrum of the pure protein sample, Fig. 2a, evidence of the stability of the drift time 
measurements over different times and different samples.
Specificity and selectivity of ATIII–Arixtra interaction
To test the specificity of the interaction between ATIII and Hp, two control experiments 
were applied by altering the structure and conformation of both ATIII and its binding 
partner.
The first control experiment was to test the binding capability of ATIII after being denatured 
due to the presence of organic solvents under harsh pH condition (49.5 water : 49.5 
methanol : 1 formic acid). Denatured ATIII was incubated with Arixtra at a molar ratio of 
1 : 3 for 12 h and sprayed in a denaturing solution (Fig. 4). A wide distribution of higher 
charge states from +47 to +23 were observed, in contrast to the narrow distribution of lower 
charge states under non-denaturing conditions. No peaks corresponding to the formation of 
ATIII–Arixtra complex were observed for these higher charge states, indicating that the 
fully denatured ATIII loses its capability to bind with Arixtra. This control eliminates the 
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concern that the complex formed between ATIII and Arixtra is non-specific, and results 
from the columbic attraction of a positively charged protein with an anionic carbohydrate. A 
mass scale expansion of the higher mass range of the denatured ATIII shows Arixtra-bound 
ATIII peaks for charge states lower than +20 (Fig. 4, inset). It is possible that these 
relatively low charge states may represent some partially folded structures of ATIII.
A broad drift time distribution with multiple features was observed for each charge state of 
denatured ATIII (data not shown) while a single sharp peak was observed for native ATIII. 
This observation indicates that the fully extended or partially unfolded structures of ATIII 
have higher flexibility than the folded structures, and adopt multiple conformations in the 
gas phase.
Previous studies have collected evidence that Hp binding sites on proteins are more than 
clustered basic amino acid residues. Instead, several structural elements (loops, α-helices 
and β-strands) have been found in Hp binding sites, implying that specific spacing and 
spatial patterns of the Hp-binding basic residues are essential in Hp-protein 
interactions.3,5,50 As in the case of ATIII–Hp binding, the folded, compact conformation of 
ATIII allows a spatial alignment of the Hp-binding basic residues which were widely 
distributed in the sequence.11,51 This alignment facilitates the formation of a basic patch 
over several helices and the N-terminal region of ATIII, which provides a binding site for 
Hp. In this control experiment, denaturing the protein led to a substantial alternation of the 
topology of the Hp binding sites,4 therefore disrupting the high affinity binding interaction 
between ATIII and Hp. Our observation revealed the importance of a folded, compact 
structure of ATIII to maintain its biological activity.
A second control experiment was performed to test the binding specificity between ATIII 
and Arixtra induced by the pattern of sulfation. Arixtra has eight sites of sulfation, with a 
sequence of: GlcNSO3, 6SO3-GlcA-GlcNSO3, 3SO3, 6SO3-IdoA2SO3-GlcNSO3, 6SO3, as 
shown in Fig. 5. The ATIII binding behavior of a Hp hexasaccharide and a Hp 
tetrasaccharide, with the structures shown in Fig. 5, were examined. The sulfation pattern of 
the Hp hexasaccharide closely resembles that of Arixtra, minus the 3-O sulfo group on the 
central glucosamine. The Hp tetrasaccharide lacks two sulfate groups and a monosaccharide 
on the non-reducing end, compared to the structure of Arixtra.
After incubating ATIII and the hexasaccharide, peaks corresponding to the hexasaccharide-
bound ATIII complex, Fig. 2d, were observed, but in much lower abundance compared to 
Arixtra, for the same incubation time and Hp concentration. Increasing the Hp concentration 
produced only a small increase in the intensity of the hexasaccharide-bound ATIII complex 
peaks. This reaction never went to completion, as can be inferred from the presence of 
unbound ATIII ions which dominated the mass spectra, even after longer incubation time. 
All of these observations indicate that the binding affinity of the hexasaccharide towards 
ATIII is much lower than Arixtra, consistent with previous studies.52 Similar results were 
observed for the binding between ATIII and the tetrasaccharide, with the peaks 
corresponding to ATIII–tetrasaccharide complex in even lower abundance (results not 
shown). Our results suggest that the hexasaccharide and tetrasaccharide both have reduced 
Zhao et al. Page 9













binding affinities for ATIII. The data confirms the significant contribution of the rare 3-O 
sulfation in Hp-protein interaction.
The drift time distributions of ATIII-negative control complexes were measured and only 
the results for +15 charge state are shown in Fig. 6. For the complex of ATIII and 
hexasaccharide, a narrow drift time distribution was observed (Fig. 6b), almost identical to 
that measured for ATIII–Arixtra complex (Fig. 6c). The drift time measured for 
hexasaccharide-bound ATIII was the same as that measured for Arixtra-bound ATIII, which 
agrees with a previous study that concluded that removing the 3-O sulfo group affected the 
equilibrium of native ATIII and activated ATIII but not the conformational change 
associated with the equilibrium.53 In other words, this control Hp oligosaccharide retains the 
specificity of binding, but has a reduced binding affinity.
In strong contrast, the Hp tetrasaccharide-ATIII complex revealed a very different behavior, 
exhibiting a broad peak with many features in the drift time spectrum, Fig. 6a, suggesting 
several structures for the complex. We interpret these as reduced specificity in the binding of 
the Hp ligand. The drift times measured for Hp tetrasaccharide-bound ATIII were smaller 
than that measured for Arixtra-bound ATIII, suggesting that the binding of the Hp 
tetrasaccharide may induce less of a conformational change within ATIII, due to the loss of 
several essential components from the specific pentasaccharide sequence.54
The results of these control experiments are consistent with the known high-affinity, specific 
interaction between ATIII and Hp. It requires more than the existence of negatively charged 
functional groups on the Hp and positively charged residues on the protein. Instead, a well-
defined three-dimensional presentation of the negatively charged groups in the Hp and a 
well-defined tertiary structure of the protein are critical to the specificity of ATIII–Arixtra 
binding.
Gas phase stability of ATIII and ATIII in complex with Arixtra
Previous studies have shown that the addition of a ligand or counter ions brings in additional 
conformational stability of protein ions against collisional activation.55,56 To test whether 
the specific binding of Arixtra has altered the conformational stability of ATIII, we 
performed a series of experiments with incremental changes in trapping collisional energy 
(CE) from 5 V to 30 V being applied to ATIII with and without Arixtra in the trap ion guide 
prior to ion mobility separation. This probes the susceptibility to collision-induced unfolding 
for native ATIII and the ATIII–Arixtra complex.
The resulting drift time distributions of +15 charge state of both ATIII and ATIII–Arixtra 
complex are shown in Fig. 7. Each drift time distribution was fitted with a minimum number 
of Gaussian distributions according to its shape using the peak analyzer in OriginPro 8.5.0 
software (OriginLab Corporation, MA), as described previously.57 Each Gaussian 
distribution generated as part of the fitness represents a potentially stabilized gas-phase 
conformation.
At a trapping CE of less than 20 V (data not shown) or equal to 20 V, a single, narrow peak 
was observed for both ATIII and ATIII–Arixtra complex, suggesting a single conformation 
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of the protein and its Hp-bound complex. The behavior of ATIII and ATIII–Arixtra complex 
started to deviate at elevated activation energy. For ATIII, a shoulder appeared on the high-
drift-time side of the original peak when the trapping CE was raised to 22.5 V. Four 
Gaussian distributions fit this drift time distribution, indicating that several partially 
unfolded or unfolded conformations of gas-phase ATIII ions were present at this collision 
energy. At a CE of 25 V, the abundance of the shoulder peak clearly increased. Two distinct 
populations of higher mobility (from 10.37 to 14.10 ms) and lower mobility (from 14.24 to 
18.11 ms) conformations were observed, each modeled by two or three Gaussian 
distributions. At a CE of 27.5 V, a broad drift time distribution resolved by eight Gaussian 
distributions was observed, indicating the presence of a series of protein conformations with 
different degrees of unfolding.
In contrast, for a range of trapping CE from 0 to 25 V, the drift time distributions of ATIII–
Arixtra complex remained unaffected, evidenced by a single, narrow peak in the drift time 
spectrum. A lower mobility peak corresponding to partially unfolded conformation of ATIII 
complex was not formed until a trapping CE as high as 27.5 V was applied, while the higher 
mobility peak corresponding to the folded structure was still the dominant peak. Clearly, 
ATIII, when complexed with Arixtra, is more stable than ATIII itself, also consistent with 
solution-phase behavior of this system.58
Previous studies showed that the binding of Hp/HS improves conformational stability of 
some proteins against heat and proteolysis.59 The additional stability is also related to the 
activity of proteins.58 Our results showed that ATIII–Arixtra complex possesses higher 
conformational stability than ATIII itself, indicating that the stability of Hp-activated ATIII 
may be a driving factor for its biological activity, which is responsible for shifting the 
conformational equilibrium towards greater stability.
Comparison of experimental CCS with theoretical CCS
Theoretical CCSs estimated from X-ray crystal structures of ATIII and Arixtra-bound ATIII 
were compared with experimentally measured CCSs. The PDB files of ATIII and ATIII–
Arixtra complex display two ATIII molecules, one in the inhibitory form and the other in the 
latent form.34 Only the inhibitory structure was used for the CCS calculation. In addition, N-
linked oligosaccharide chains are present in the structures in both PDF files. We chose to 
leave the oligosaccharides out of the CCS calculation. The N-linked oligosaccharides are not 
thought to participate in Hp binding, so they are expected to contribute equally to the CCS 
of ATIII and ATIII–Arixtra complex. As we are interested in the conformation change 
within the protein rather than the absolute measurement of CCSs, the glycosylation-free 
estimation of CCS should allow us a direct and simple observation of the conformational 
change. We added the missing H-atoms to the crystal structures since their effect may not be 
ignored in the accurate estimation of the subtle conformational change.
The calculated CCSs of native ATIII were 3010.1 Å2 estimated using PA and 3900.5 Å2 
estimated using TM. The calculated CCSs of Arixtra-bound ATIII were 3120.2 Å2 estimated 
using PA and 4033.3 Å2 estimated using TM (Table 3). The experimental CCSs for the 
lowest charge state of native ATIII and ATIII–Arixtra complex were 3467.9 Å2 and 3607.1 
Å2, respectively, comparable with those theoretical measurements.
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The experimental CCS is approximately 12.1% less than the theoretical CCSs estimated 
using TM and 15.4% higher than that estimated using PA. These observations are consistent 
with previous studies on other proteins, which found that reasonable experimental CCSs 
should lie in between the theoretical estimates made using PA and TM. The experimental 
CCSs should be smaller than TM results, due to the collapsed structure of protein ions in the 
gas-phase in response to desolvation.14,60,61 Ignoring the long-range interaction with the 
neutral gas, collision effect and scattering process, PA results are on average 15% smaller 
than the experimental CCSs,62 in agreement with our observation.
It is noteworthy that there is close agreement between the relative changes in the CCS 
measured experimentally versus those determined by theoretical calculations. The averaged 
experimental conformational change was 3.6%, while the calculated conformational change 
was 3.7% for PA results and 3.4% for TM results, respectively. The contribution of the 
protein conformational change to the overall increase in the CCS was calculated to be 47.8% 
using the PA method, and 52.5% using the TM method. It would be safe to say that about 
50% of the increase in CCS for Arixtra bound ATIII comes from the protein, while the 
remaining increase is due to the presence of Arixtra itself. These results show that the 
TWIMS experiment generates gas-phase ATIII and Arixtra-bound ATIII ions with 
conformations that match the solution structure closely, thus allowing and accurate 
measurement of the conformational changes in ATIII upon Arixtra binding.
Conclusions
TWIMS was found to provide data that is consistent with the known details of ATIII–
Arixtra binding. Our mass spectra showed the formation of a 1 : 1 complex of ATIII with 
Arixtra, and the corresponding IM spectra were consistent with a single, folded gas-phase 
conformation of ATIII in its free and Arixtra-bound form, evidenced by a single narrow drift 
time distribution in both cases. CCSs derived from these data showed that the binding of 
Arixtra to ATIII caused a 3.6% increase of ATIII’s CCS. Both the absolute CCSs of ATIII 
and Arixtra-bound ATIII ions as well as the degree of CCS change were in agreement with 
theoretical CCSs calculated using coordinates from their X-ray crystal structures.
Furthermore, the selectivity and specificity of Hp-ATIII binding known from solution 
measurements appeared to survive the translation of the ions into the gas-phase, as revealed 
by the control experiments. Disrupting the folded structure of ATIII caused the loss of its 
binding affinity towards Arixtra. Removing the 3-O sulfo group from the known Hp binding 
sequence resulted in substantial reduction of the abundance of ATIII–Hp complex but did 
not change the drift time behavior, as expected based on known solution behavior. These 
two control experiments not only confirmed the biological relevance of the native ATIII and 
Arixtra-bound ATIII ions that we observed, but also provided evidence to support the 
existence and significance of the specificity of the ATIII–Hp interaction. A control 
experiment using a Hp tetrasaccharide with a different pattern of sulfation than the known 
consensus sequence not only showed a substantially reduced affinity for ATIII, but also 
showed a reduction in specificity of binding, evidenced by a broad drift time distribution, 
consistent with a variety of structures for the complex. Moreover, the TWIMS measurement 
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showed the stabilizing effect of Arixtra binding on the ATIII folded structure. This result 
also matched solution studies of ATIII and its Hp complexes.
Collectively, these results highlight the advantages of TWIMS for investigating GAG–
protein interactions at the molecular level. Future applications of this approach will be 
useful for gaining a better understanding of the biological processes mediated by other 
GAG–protein interactions.
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The calibration curves were constructed at three wave heights, combining data from 
cytochrome c, myoglobin, avidin, BSA and concanavalin A, displayed as literature CCS vs. 
effective drift time for each charge state.
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Electrospray ionization mass spectra, obtained under non-denaturing conditions, of (a) 
ATIII; (b) ATIII incubated with Arixtra for 1 h; (c) ATIII incubated with Arixtra for 12 h; 
(d) ATIII incubated with the Arixtra-like hexasaccharide, minus 3-O-sulfation, for 12 h.
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Drift timed distributions (ms) of the dominant charge states (+14–+16) of native ATIII and 
Arixtra-bound ATIII, at a wave height of 17 V.
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Electrospray ionization mass spectra of denatured ATIII with (upper) and without (lower) 
addition of Arixtra; The inset shows an expansion of the mass range (2500 m/z–3000 m/z) of 
the two spectra. Unbound ATIII peaks were labeled with green and Arixtra-bound peaks 
were labeled with purple.
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Structures of Arixtra (dp5 with 8 SO3) (upper), modified Arixtra (dp6 with 7 SO3) (middle) 
and the Hp tetrasaccharide (dp4 with 6 SO3) (below).
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Drift time distributions (ms) of the +15 charge state of ATIII in complex with compounds, 
shown in Fig. 5, the Hp tetrasaccharide (a), modified Arixtra (b) and Arixtra (c), at a wave 
height of 17 V.
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Experimental drift time distributions (ms) of +15 charge state of ATIII (left panels) and 
ATIII–Arixtra complex (right panels) as a function of trapping CE varying from 20 V to 
27.5 V are shown in 2.5 V increments. The normalized experimental drift time distribution 
is shown by the blue dots. The fit of the data to a series of Gaussian distributions is shown in 
green, and the sum of the component Gaussians is shown in red.
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Table 1
Calibrants
Calibrants and mass Charge CCS (He, Å2)
Avidin 17 3640
64 kDa 18 3640
Concanavalin A 20 5550
102 kDa 21 5550
22 5480
23 5450
Cytochrome c 11 2303
















Bovine serum albumin 15 4100
66.5 kDa 16 4060
17 4040
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Table 2
CCSs measured experimentally
Charge state Free ATIII CCS (Å2) Arixtra-bound ATIII CCS (Å2) CCS increase (Å2) CCS increase %
14 3467.9 ± 14.5 3607.1 ± 16.6 123.5 ± 6.6 3.4
15 3439.8 ± 8.1 3573.1 ± 7.0 133.2 ± 2.3 3.7
16 3462.3 ± 17.6 3591.4 ± 15.9 133.0 ± 8.4 3.7
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Table 3
CCSs calculated using MOBCAL
System PA method (Å2) TM method (Å2)
ATIII–Arixtra complex 3120.2 ± 3.2 4033.3 ± 14.5
ATIII 3010.1 ± 2.7 3900.5 ± 9.7
CCS increase% 3.7 3.4
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